Cognitive and Performance Enhancing Compositions for Diverse Applications

Publication ID: 24-11857525_0002_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Cognitive and Performance Enhancing Compositions for Diverse Applications,” Published Technical Disclosure No. 24-11857525_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857525_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,525.

Summary of the Inventive Concept

The present inventive concept relates to novel applications of specialized immunonutrition supplements, originally developed for treating surgery-induced cachexia, in diverse fields such as enhancing cognitive function, reducing anxiety, improving athletic performance, treating depression, and enhancing mental clarity and focus.

Background and Problem Solved

The original patent disclosed compositions and methods for treating or preventing surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines. However, the patent's scope was limited to the specific application of treating surgery-induced cachexia. The present inventive concept addresses the need for novel applications of these specialized immunonutrition supplements in other industries and fields, leveraging their potential benefits for diverse populations.

Detailed Description of the Inventive Concept

The inventive concept encompasses systems and methods for administering specialized immunonutrition supplements comprising L-arginine, omega-3 fatty acids, vitamin A, and dietary nucleotides to individuals in need of cognitive, performance, or emotional enhancement. The supplements are tailored to provide specific daily doses of each component, as outlined in the new claims. For instance, the composition for enhancing cognitive function in individuals with ADHD includes a daily dose of 5-30g of L-arginine, while the composition for reducing symptoms of anxiety in individuals undergoing a stressful event includes a daily dose of 1.0-5.0g of eicosapentaenoic acid and docosahexaenoic acid in total.

Novelty and Inventive Step

The novelty of the present inventive concept lies in the unexpected application of specialized immunonutrition supplements, originally developed for treating surgery-induced cachexia, in diverse fields such as cognitive enhancement, anxiety reduction, athletic performance improvement, depression treatment, and mental clarity and focus enhancement. The inventive step resides in the recognition of the supplements' potential benefits in these new areas and the tailoring of the compositions and methods to address specific needs and populations.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include varying the daily doses of each component, combining the supplements with other nutrients or compounds, or developing new formulations for specific applications. Variations may also include adapting the compositions and methods for use in different populations, such as children or elderly individuals, or for addressing specific health conditions, such as chronic fatigue syndrome or post-traumatic stress disorder.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in various industries, including pharmaceuticals, nutraceuticals, sports nutrition, and mental health. The target markets include individuals with ADHD, athletes seeking performance enhancement, individuals experiencing anxiety or depression, and those seeking to improve their mental clarity and focus. The inventive concept's broad applicability and potential benefits position it for significant market impact and growth.

Original Patent Information

Patent NumberUS 11,857,525
TitleTreatment or prevention of surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines
Assignee(s)SOCIÉTÉ DES PRODUITS NESTLÉ S.A.